Definition and Specifications of Osteoporosis - Pipeline Review, H1 2017
Osteoporosis - Pipeline Review, H1 2017 is a new market research publication announced by Reportstack. This report provides an overview of the Osteoporosis (Metabolic Disorders) pipeline landscape.
Osteoporosis, or thinning bones, makes bones weak and more likely to break. Risk factors for osteoporosis include aging, being female, low body weight, low sex hormones or menopause, smoking, and some medications. Signs and symptoms include back pain, caused by a fractured or collapsed vertebra, loss of height over time, a stooped posture, a bone fracture that occurs much more easily than expected. Prevention and treatment include calcium and vitamin D, exercise, and osteoporosis medications.
Complete report available @ Osteoporosis - Pipeline Review, H1 2017
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Osteoporosis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Osteoporosis (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Osteoporosis (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Osteoporosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 6, 5, 5, 11, 57, 11 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 10 and 13 molecules, respectively.
Osteoporosis (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoporosis (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Osteoporosis (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Osteoporosis (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Osteoporosis (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Osteoporosis (Metabolic Disorders)
- The pipeline guide reviews pipeline therapeutics for Osteoporosis (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Osteoporosis (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Osteoporosis (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Osteoporosis (Metabolic Disorders)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Osteoporosis (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Osteoporosis (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Osteoporosis (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Osteoporosis (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
Addex Therapeutics Ltd Alize Pharma SAS Alvogen Korea Co Ltd Amgen Inc Amura Holdings Ltd BiologicsMD Inc Bone Biologics Corp Bristol-Myers Squibb Company Cellmid Ltd ChoDang Pharm Co Ltd Chugai Pharmaceutical Co Ltd Corium International Inc Critical Pharmaceuticals Ltd Daiichi Sankyo Company Ltd ElexoPharm GmbH EndoCeutics Inc Entera Bio Ltd Enteris BioPharma Inc Enzo Biochem Inc F. Hoffmann-La Roche Ltd Gador SA GL Pharm Tech Corp Glide Pharmaceutical Technologies Ltd Hanmi Pharmaceuticals Co Ltd Haoma Medica Ltd Immunovo BV Immunwork Inc Intas Pharmaceuticals Ltd Ipsen SA Kaken Pharmaceutical Co Ltd Lead Discovery Center GmbH Ligand Pharmaceuticals Inc Lotus Pharmaceutical Co Ltd Lupin Ltd Merck & Co Inc Mereo Biopharma Group Plc NIBEC Omeros Corp Oncobiologics Inc Osteologix Holdings Plc Paras Biopharmaceuticals Finland Oy Pfenex Inc PhytoHealth Corp R Pharm Ribomic Inc Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Shin Poong PharmCo Ltd Sinil Pharmaceutical Co Ltd Stelis Biopharma Pvt Ltd Sumitomo Dainippon Pharma Co Ltd Terpenoid Therapeutics Inc TSH Biopharm Corporation Ltd Uni-Bio Science Group Ltd Viking Therapeutics Inc Wroclawskie Centrum Badan EIT+ Sp z oo Yooyoung Pharm Co Ltd Zydus Cadila Healthcare Ltd
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
ReportstackMarket Research
###
posted by Reportstack @ 23:23
0 Comments
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home